Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of ($0.13), $0.05 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $28.22 million versus the consensus estimate of $28.15 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.